Alprostadil

Alprostadil is the pharmaceutical name for synthetically produced prostaglandin E1, one of a family of prostaglandins that the body makes from fatty acids to regulate blood flow, inflammation, and smooth muscle tone. As a drug it behaves as a potent vasodilator: it widens blood vessels, relaxes smooth muscle, and inhibits the clumping of platelets ^[1]. Because it is broken down quickly in the body, it is usually given by continuous infusion or by local application to the tissue where its action is wanted.

In the treatment of erectile dysfunction, alprostadil is administered either by injection into the erectile tissue of the penis or as a small pellet placed into the urethra. By relaxing the smooth muscle of the penile arteries and erectile chambers, it increases blood inflow and produces an erection. Reviews of erectile dysfunction therapy describe intracavernosal alprostadil as a highly effective option and the injectable agent of first choice among injection therapies, while the urethral form is generally less effective ^[1][5]. It is often used when oral medications are unsuitable or have not worked ^[5].

A distinct and life-saving use is in newborns with so-called ductal-dependent congenital heart defects, in which survival depends on keeping open the ductus arteriosus, a vessel that normally closes soon after birth. Given as an intravenous infusion, alprostadil relaxes the ductal smooth muscle and maintains this connection, preserving blood flow to the lungs or body until corrective surgery can be performed ^[2][3]. Studies in critically ill newborns confirm that the infusion reliably maintains ductal patency, with side effects that are usually transient and manageable ^[3].

Alprostadil and related prostaglandins have also been studied for severe peripheral arterial disease, including critical limb ischemia that cannot be corrected surgically. A systematic review found that prostanoids did not reduce the risk of amputation but offered small improvements in rest pain and the healing of leg ulcers, at the cost of more frequent side effects ^[4]. This mixed picture means their role in limb ischemia remains limited and carefully weighed ^[4].

Alprostadil has been in medical use since the early 1980s and is a prescription-only medicine. It is marketed under several brand names for its different indications and is available as a solution for intravenous infusion, as a powder or solution for injection into the penis, as an intraurethral suppository, and, in some markets, as a topical cream. Related prostaglandin E1 derivatives, such as misoprostol and lubiprostone, are used for entirely different purposes ^[1].

Alprostadil is prescription only and its risks depend on how it is used. For erectile dysfunction, injections can cause penile pain, bruising, and, over time, scarring or fibrous nodules, and the most serious risk is priapism, a painful erection lasting more than a few hours that is a medical emergency needing prompt treatment to prevent lasting damage. It is not for men in whom erections are inadvisable or who are prone to priapism. In newborns, the infusion commonly causes apnea, meaning pauses in breathing, along with fever, flushing, and low blood pressure, so babies are monitored closely with breathing support available. It should not be combined with other erectile drugs without medical advice.

Alprostadil potentiates bleeding when combined with antiplatelet or anticoagulant medications. As a prostaglandin E1 analog, alprostadil inhibits platelet aggregation and promotes vasodilation, and these effects are additive with other agents that impair hemostasis; concurrent use with aspirin, clopidogrel, warfarin, heparin, or other anticoagulants significantly increases bleeding risk ^[7]. In a retrospective clinical study of epidural steroid injection, patients receiving alprostadil (limaprost alfadex, a derivative) alongside antithrombotic therapy experienced no statistically significant increase in epidural hematoma compared to those who discontinued the medication, suggesting the interaction is manageable in controlled settings with appropriate monitoring ^[8].

Checking a whole stack? Run it through interactions + stacks.

Alprostadil is a manufactured form of prostaglandin E1, a signaling lipid the body produces naturally, and its medical history follows two very different applications. Its first major use, beginning in the 1970s and 1980s, was in newborns with certain congenital heart defects, where an intravenous infusion (marketed as Prostin VR) keeps the ductus arteriosus open until corrective surgery can be performed. In the 1990s it was developed for erectile dysfunction, with the injectable form Caverject approved by the United States Food and Drug Administration in 1995 and a urethral pellet system, MUSE, following in 1996. It thus became one of the first effective pharmacologic treatments for erectile dysfunction, predating the oral PDE5 inhibitors.

Alprostadil is respected as a highly effective option for erectile dysfunction, often producing a response even in men who do not benefit from oral tablets, which has kept it clinically relevant since the arrival of sildenafil and its successors. In neonatal cardiology it is regarded as a genuinely life-saving intervention, buying critical time for infants with duct-dependent heart defects. Because it acts locally and is broken down very quickly, its effects are short-lived and confined largely to the site of administration, which limits systemic side effects. The main drawbacks are practical: it must be delivered by injection or urethral application rather than by mouth, and penile pain or, rarely, prolonged erection can occur.